

## United Kingdom (UK) Prescribing Information: Vimkunya®▼, Chikungunya vaccine (recombinant, adsorbed).

Please refer to the Summary of Product Characteristics (SPC) before prescribing

**Vimkunya® composition:** 0.8 ml suspension in a single-dose pre-filled syringe. One dose (0.8 ml) contains 40 µg protein of chikungunya virus (CHIKV) virus-like particles (VLP) adsorbed on aluminium hydroxide, hydrated. Please see SPC for list of excipients.

**Therapeutic indications:** VIMKUNYA is indicated for active immunisation for the prevention of disease caused by CHIKV in individuals 12 years and older.

**Dosage and administration:** A single dose of 0.8 ml should be administered by intramuscular (IM) injection in the deltoid muscle. The pre-filled syringe should be vigorously shaken immediately before use to obtain a homogeneous suspension.

**Elderly:** No dose adjustment is required in elderly individuals ≥ 65 years of age.

**Paediatric population:** The safety and efficacy of VIMKUNYA in children below 12 years of age have not been established.

**Booster:** The need for a booster dose has not yet been evaluated.

**Contraindications:** Hypersensitivity to the active substance or to any of the excipients listed in SPC.

**Special warnings and precautions: Off-label administration:** VIMKUNYA must not be injected intravenously, intradermally, or subcutaneously.

**Hypersensitivity and anaphylaxis:** In the event of an acute anaphylactic reaction, appropriate medical treatment must be immediately available.

**Immunocompromised individuals:** The safety and efficacy of VIMKUNYA has not been assessed in such individuals. It is not known whether immunocompromised individuals will elicit the same response as immunocompetent individuals.

**Anxiety-related reactions:** As with all injectable vaccines, anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur. It is important that precautions are in place to avoid injury from fainting.

**Concurrent illness:** Vaccination should be postponed in individuals with acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.

**Thrombocytopenia and coagulation disorders:** As with other IM injections, the vaccine should be given with caution to individuals receiving anti-coagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) due to bleeding or bruising which may occur in these individuals.

**Limitations of vaccine effectiveness:** As with any vaccine, protection may not be elicited after vaccination in all persons. It is recommended to continue personal protection measures against mosquito bites after vaccination.

**Excipients:** This vaccine contains less than 1 mmol potassium (39 mg) per dose, essentially 'potassium-free'. This vaccine contains less than 1 mmol sodium (23 mg) per dose, essentially 'sodium-free'.

**Interactions:** Interaction studies with other medicinal products have not been performed. **Concomitant administration** with other vaccines has not been studied.

**Fertility, pregnancy and lactation: Pregnancy:** There is limited amount of data from the use of VIMKUNYA in pregnant women. These data are not sufficient to conclude on the absence of potential effects of VIMKUNYA on pregnancy, embryo-foetal development, parturition and post-natal development. Decisions to administer VIMKUNYA during pregnancy should take into consideration the individual's risk of exposure to wild-type CHIKV, gestational age, and risks to the foetus or neonate.

**Breast-feeding:** It is unknown if VIMKUNYA is excreted in human milk. A risk to the breastfed child cannot be excluded. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VIMKUNYA and any potential adverse effects on the breastfed child.

**Fertility:** No specific studies have been performed on fertility.

**Undesirable effects: Common adverse reaction reported in clinical trials:** The most common local adverse reaction at the injection site after vaccine administration was injection site pain (24.0%). The most common systemic adverse reactions observed after vaccination were fatigue (17.8%), headache (16.7%) and myalgia (16.5%). Please refer to SPC for other adverse reactions.

**Special precautions for storage:** Store in a refrigerator (2°C to 8°C) and protect from light. Do not freeze.

**Package quantities:** 1 single-dose pre-filled syringe (0.8 ml) without needle.

**Basic NHS cost:** £115

**Legal category:** POM.

**Marketing authorisation number:** PL 40365/0008

**Marketing authorisation holder:** Bavarian Nordic A/S,  
Philip Heymans Alle 3, 2900 Hellerup, Denmark

**Please refer to the Summary of Product**

**Characteristics prior to prescribing:**

[www.medicines.org.uk/emc](http://www.medicines.org.uk/emc)

**Date of preparation:** June 2025, UK-VIM-2500002

**Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Bavarian Nordic: [drug.safety@bavarian-nordic.com](mailto:drug.safety@bavarian-nordic.com)**